Clinical Trials Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Generalized Anxiety Disorder
Data show Lunesta improved insomnia in patients with co-existing generalized anxiety disorder
January 1st, 2007
Sepracor Inc. (SEPR) announces the presentation of results from a Phase IV, 595-patient, double-blind, placebo-controlled, ten-week study evaluating the efficacy and safety of Lunesta brand eszopiclone in patients with insomnia and co-existing generalized anxiety disorder (GAD). The results were presented at the annual meeting of the American College of Neuropsychopharmacology in Hollywood, Florida. In this study, patients who met DSM-IV (1) criteria for both insomnia and GAD were randomized to receive nightly Lexapro brand escitalopram oxalate 10 mg, which is approved for the treatment of GAD, and either Lunesta 3 mg (n=294) or placebo (n=301) for...
Source: Clinical Trials Week (2007-01-01)
|
